862377-33-1

Basic information

• Product Name: RU 346
• CAS NO: 862377-33-1
• Molecular Weight: 319.444
• Mol File: 862377-33-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: RU 346(CAS DataBase Reference)
• NIST Chemistry Reference: RU 346(862377-33-1)
• EPA Substance Registry System: RU 346(862377-33-1)

Safety Data

• Hazardous Substances Data: 862377-33-1(Hazardous Substances Data)

Usage

Description

RU 346, also known as (2S,3R,11bS)-Dihydrotetrabenazine, is an enantiomer of (2R,3S,11bR)-Dihydrotetrabenazine (D454925). It is a derivative of Tetrabenazine, which is a potent inhibitor of vesicular monoamine transporter 2 (VMAT2). RU 346 has potential applications in the treatment of various diseases, particularly Huntington's disease and other hyperkinetic disorders.

Uses

Used in Pharmaceutical Industry:
RU 346 is used as a potential drug candidate for treating Huntington's disease and other hyperkinetic disorders due to its potent inhibitory effect on vesicular monoamine transporter 2 (VMAT2). Its ability to modulate the levels of monoamines in the brain makes it a promising therapeutic agent for these conditions.
Additionally, RU 346 and its derivatives may be used in the development of novel drug delivery systems to enhance their efficacy and bioavailability, further improving their therapeutic potential in treating the targeted diseases.

Upstream product

• 58-46-8 (3R^*,11bR^*)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzoquinolizin-2-one 
• 924854-62-6 (2R,3S,11bS)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol 
• 1300639-88-6 (8aR,9aS,10aS)-5,8,8a,9a,10,10a-hexahydro-2,3-dimethoxy-8a-(2-methylpropyl)-6H-benz[a]oxireno[g]quinolizine 
• 1215167-80-8 (11bS)-1,6,7,11b-tetrahydro-9,10-dimethoxy-3-(2-methylpropyl)-4H-benzo[a]quinolizine 
• 1026016-84-1 (3S,11bS)-tetrabenazine 
• 862287-33-0 C₁₉H₂₇NO₃ 
• 862287-35-2 C₂₉H₃₆F₃NO₅ 
• 920265-22-1 C₁₉H₂₇NO₃ 

Relevant articles and documents

Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors

Tetrabenazine (TBZ) ((±)-1) and dihydrotetrabenazines (DHTBZ) are potent inhibitors of VMAT2. Herein, a practical chemical resolution of (±)-1 and stereoselective synthesis of all eight DHTBZ stereoisomers are described. The result of VMAT2 binding assay revealed that (+)-1 (Ki = 4.47 nM) was 8000-fold more potent than (-)-1 (Ki = 36,400 nM). Among all eight DHTBZ stereoisomers, (2R,3R,11bR)-DHTBZ ((+)-2: Ki = 3.96 nM) showed the greatest affinity for VMAT2. The (3R,11bR)-configuration appeared to play a key role for VMAT2 binding. In summary, (+)-1, (+)-2, and their derivatives warrant further studies in order to develop more potent and safer drugs for the treatment of chorea associated with Huntington's disease and other hyperkinetic disorders.

3 , llB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE OR AN INFLAMMATION

The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a proliferative disease or an inflammatory disease, the compound being 3,1lb-cis-dihydrotetrabenazine or a pharmaceutically acceptable sal